ADAGIO MEDICAL HOLDINGS INC (ADGM) Fundamental Analysis & Valuation

NASDAQ:ADGM • US00534B1008

Current stock price

1.26 USD
0 (0%)
Last:

This ADGM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ADGM Profitability Analysis

1.1 Basic Checks

  • ADGM had negative earnings in the past year.
  • In the past year ADGM has reported a negative cash flow from operations.
  • In the past 5 years ADGM reported 4 times negative net income.
  • In the past 5 years ADGM always reported negative operating cash flow.
ADGM Yearly Net Income VS EBIT VS OCF VS FCFADGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • ADGM has a worse Return On Assets (-250.89%) than 91.01% of its industry peers.
Industry RankSector Rank
ROA -250.89%
ROE N/A
ROIC N/A
ROA(3y)-230.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADGM Yearly ROA, ROE, ROICADGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ADGM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADGM Yearly Profit, Operating, Gross MarginsADGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

0

2. ADGM Health Analysis

2.1 Basic Checks

  • ADGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ADGM has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ADGM has been reduced compared to a year ago.
ADGM Yearly Shares OutstandingADGM Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
ADGM Yearly Total Debt VS Total AssetsADGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -6.46, we must say that ADGM is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ADGM (-6.46) is worse than 73.55% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.46
ROIC/WACCN/A
WACC7.86%
ADGM Yearly LT Debt VS Equity VS FCFADGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • ADGM has a Current Ratio of 0.84. This is a bad value and indicates that ADGM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ADGM has a Current ratio of 0.84. This is amonst the worse of the industry: ADGM underperforms 88.89% of its industry peers.
  • ADGM has a Quick Ratio of 0.84. This is a bad value and indicates that ADGM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ADGM has a Quick ratio of 0.68. This is amonst the worse of the industry: ADGM underperforms 87.30% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.68
ADGM Yearly Current Assets VS Current LiabilitesADGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M

3

3. ADGM Growth Analysis

3.1 Past

  • The earnings per share for ADGM have decreased strongly by -229.28% in the last year.
  • ADGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -68.79%.
EPS 1Y (TTM)-229.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.56%
Revenue 1Y (TTM)-68.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • ADGM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.15% yearly.
  • The Revenue is expected to grow by 80.03% on average over the next years. This is a very strong growth
EPS Next Y65.5%
EPS Next 2Y34%
EPS Next 3Y21.17%
EPS Next 5Y15.15%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y45.02%
Revenue Next 5Y80.03%

3.3 Evolution

ADGM Yearly Revenue VS EstimatesADGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2M 4M 6M
ADGM Yearly EPS VS EstimatesADGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5

1

4. ADGM Valuation Analysis

4.1 Price/Earnings Ratio

  • ADGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADGM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADGM Price Earnings VS Forward Price EarningsADGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADGM Per share dataADGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ADGM's earnings are expected to grow with 21.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34%
EPS Next 3Y21.17%

0

5. ADGM Dividend Analysis

5.1 Amount

  • ADGM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ADGM Fundamentals: All Metrics, Ratios and Statistics

ADAGIO MEDICAL HOLDINGS INC

NASDAQ:ADGM (3/25/2026, 12:51:19 PM)

1.26

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12
Earnings (Next)04-06
Inst Owners33.42%
Inst Owner Change42.92%
Ins Owners3.47%
Ins Owner Change2.24%
Market Cap26.69M
Revenue(TTM)137.00K
Net Income(TTM)-79.15M
Analysts82.86
Price Target4.08 (223.81%)
Short Float %0.71%
Short Ratio1.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 194.79
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.75
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.01
BVpS-0.06
TBVpS-1.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -250.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-230.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.86%
Cap/Sales 1140.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.68
Altman-Z -6.46
F-Score2
WACC7.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-229.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.56%
EPS Next Y65.5%
EPS Next 2Y34%
EPS Next 3Y21.17%
EPS Next 5Y15.15%
Revenue 1Y (TTM)-68.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y45.02%
Revenue Next 5Y80.03%
EBIT growth 1Y8.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.89%
EBIT Next 3Y10.34%
EBIT Next 5Y6.23%
FCF growth 1Y-3129.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2918.24%
OCF growth 3YN/A
OCF growth 5YN/A

ADAGIO MEDICAL HOLDINGS INC / ADGM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ADAGIO MEDICAL HOLDINGS INC (ADGM) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ADGM.


What is the valuation status for ADGM stock?

ChartMill assigns a valuation rating of 1 / 10 to ADAGIO MEDICAL HOLDINGS INC (ADGM). This can be considered as Overvalued.


What is the profitability of ADGM stock?

ADAGIO MEDICAL HOLDINGS INC (ADGM) has a profitability rating of 0 / 10.


What is the expected EPS growth for ADAGIO MEDICAL HOLDINGS INC (ADGM) stock?

The Earnings per Share (EPS) of ADAGIO MEDICAL HOLDINGS INC (ADGM) is expected to grow by 65.5% in the next year.